Radiopharmaceutical firm Cellectar Biosciences said that a new study published in PLOS One found that its phospholipid ether (PLE) analog agents showed efficacy for detecting colorectal cancer.
In the study, published online October 6, a research team led by Dr. Dustin Deming of the University of Wisconsin determined that Cellectar's CLR1502 agent accumulated in intestinal tumors and was able to distinguish malignant from nonmalignant tissues in an animal model of colon cancer. It could also highlight regional lymph nodes, Cellectar said.
In addition, the researchers shared results of a phase I clinical trial for Cellectar's iodine-131 CLR1404 investigational PET tracer/therapeutic agent. The agent accumulated in human colon cancer metastases, showing its potential value in colorectal cancer treatment and also as a PET imaging agent, Cellectar said.